{"id":"bhv-4157","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Paresthesia"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4297673","moleculeType":"Protein","molecularWeight":"455.85"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"5-HT1F receptor agonists work by binding to serotonin receptors on trigeminal nerve terminals and inhibiting the release of pro-inflammatory neuropeptides like calcitonin gene-related peptide (CGRP). This reduces neuroinflammation and pain signaling in migraine pathways. BHV-4157 is designed as a selective 5-HT1F agonist with potential advantages in migraine acute treatment.","oneSentence":"BHV-4157 is a selective serotonin 5-HT1F receptor agonist that reduces neuronal activity and neuropeptide release to treat acute migraine.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:11.165Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute migraine treatment"}]},"trialDetails":[{"nctId":"NCT04708834","phase":"PHASE3","title":"Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder","status":"TERMINATED","sponsor":"Biohaven Pharmaceuticals, Inc.","startDate":"2021-03-30","conditions":"Obsessive Compulsive Disorder","enrollment":772},{"nctId":"NCT03299166","phase":"PHASE2, PHASE3","title":"Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder","status":"COMPLETED","sponsor":"Biohaven Pharmaceuticals, Inc.","startDate":"2017-12-19","conditions":"Obsessive-Compulsive Disorder","enrollment":426},{"nctId":"NCT06529146","phase":"","title":"Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biohaven Therapeutics Ltd.","startDate":"2019-03-18","conditions":"Spinocerebellar Ataxias","enrollment":909},{"nctId":"NCT06034886","phase":"","title":"Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)","status":"AVAILABLE","sponsor":"Biohaven Pharmaceuticals, Inc.","startDate":"","conditions":"SCA, Spinocerebellar Ataxias","enrollment":""},{"nctId":"NCT06552260","phase":"EARLY_PHASE1","title":"A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma","status":"RECRUITING","sponsor":"Ugonma Chukwueke","startDate":"2025-02-19","conditions":"Glioblastoma, Recurrent Glioblastoma, Brain Tumor","enrollment":27},{"nctId":"NCT03970447","phase":"PHASE2, PHASE3","title":"A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma","status":"RECRUITING","sponsor":"Global Coalition for Adaptive Research","startDate":"2019-07-30","conditions":"Glioblastoma","enrollment":1280},{"nctId":"NCT03408080","phase":"PHASE3","title":"Open Pilot Trial of BHV-4157","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2017-12-15","conditions":"Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2","enrollment":24},{"nctId":"NCT03829241","phase":"PHASE3","title":"Randomized Trial of Adult Participants With Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Biohaven Pharmaceuticals, Inc.","startDate":"2019-02-19","conditions":"Generalized Anxiety Disorder","enrollment":881},{"nctId":"NCT04899921","phase":"PHASE2","title":"Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-06-30","conditions":"Melanoma, Metastatic Melanoma","enrollment":1},{"nctId":"NCT03229278","phase":"PHASE1","title":"Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2017-10-03","conditions":"Lymphoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma","enrollment":14},{"nctId":"NCT03605667","phase":"PHASE2","title":"Study of BHV-4157 in Alzheimer's Disease","status":"COMPLETED","sponsor":"Biohaven Pharmaceuticals, Inc.","startDate":"2018-07-31","conditions":"Alzheimer Disease","enrollment":350}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BHV-4157","genericName":"BHV-4157","companyName":"Biohaven Therapeutics Ltd.","companyId":"biohaven-therapeutics-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BHV-4157 is a selective serotonin 5-HT1F receptor agonist that reduces neuronal activity and neuropeptide release to treat acute migraine. Used for Acute migraine treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}